(Q33694866)

28 July 2017

title

Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients (English)

1 reference

28 July 2017

1 reference

1 reference

2

Björn Nodin

0 references

Karin Jirström

8

object named as

Karin Jirström

1 reference

28 July 2017

Ulf-Håkan Stenman

5

1 reference

28 July 2017

Alexander Gaber

1

1 reference

28 July 2017

Björn Nodin

2

1 reference

28 July 2017

Kristina Hotakainen

3

1 reference

28 July 2017

Elise Nilsson

4

1 reference

28 July 2017

Anders Bjartell

6

1 reference

28 July 2017

Helgi Birgisson

7

1 reference

28 July 2017

language of work or name

English

0 references

publication date

17 September 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

10

1 reference

28 July 2017

page(s)

498

1 reference

Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Adjuvant Therapy for completely resected Stage II Colon Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

The role of SPINK1 in ETS rearrangement-negative prostate cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Global cancer statistics, 2002

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Tailored chemotherapy for colorectal cancer: a new approach to therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Pancreatic secretory trypsin inhibitor as an acute phase reactant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Serum levels of immunoreactive PSTI in acute abdominal disorders, with special reference to a possible extrapancreatic PSTI production.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Postoperative elevation of serum pancreatic secretory trypsin inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Biology and function of tumor-associated trypsin inhibitor, TATI.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-498

Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-498

CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-498

Tumour-associated trypsin inhibitor and renal cell carcinoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2946315

Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas

30 October 2018

1 reference

12 December 2020

Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer

1 reference

12 December 2020

Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies

1 reference

12 December 2020

A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids

1 reference

12 December 2020

Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy

1 reference

12 December 2020

Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients

1 reference

12 December 2020

The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease

1 reference

12 December 2020

Evaluation of Tati and Other Markers in Solid Tumors

1 reference

12 December 2020

Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA

1 reference

12 December 2020

Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242

1 reference

12 December 2020

TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder

1 reference

12 December 2020

Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-498

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference